by Stephane Cailmail | 7 Feb 2020 | Actualités générales, General news, Publications, Research
Immunotherapy is a treatment that aims to educate our immune system against cancer cells. This treatment resulted in a long-term response in patients with metastatic melanoma (40-60%) with in some cases total tumour regression. The challenge is now that the maximum...
by Stephane Cailmail | 7 Feb 2020 | Actualités générales, Publications
Dendrogenin A (DDA) is a tumor suppressor mammalian cholesterol-derived metabolite and a new class of ligand of the Liver X receptor (LXR), which displays tumor cell differentiation. In human and mouse breast adenocarcinoma cells, DDA-induced cell differentiation was...
![Focus: Anti-TNF[alpha] antibodies improve immunotherapy in melanoma](https://www.crct-inserm.fr/wp-content/uploads/2018/03/Segui_Meyer_2.jpg)
by Sébastien Guibert | 16 Mar 2018 | Actualités générales
Melanoma is a poor-prognosis skin cancer. Immunotherapy based on the use of monoclonal antibodies (anti-CTLA-4 and anti-PD-1) activates the immune system to fight melanoma and has improved the prognosis of this cancer. Those antibodies block checkpoints, which act as...
by Sébastien Guibert | 11 Dec 2017 | Actualités générales
A 2-years post-doctoral position is open in CRCT’s team 19 (ONCOSARC / F. Chibon), starting 01/01/2018 Description The ONCOSARC team of CRCT is focused on deciphering pleomorphic sarcoma oncogenesis. Since these tumors are characterized by a highly rearranged...
